PC-SPES: A brief overview

Integrative Cancer Therapies

Volumn 1, Issue 3, 2002, Pages 271-286

  Cordell, Geoffrey A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DIETHYLSTILBESTROL; FLAVONOID; HERBACEOUS AGENT; HERBAL PREPARATION PC SPES; HERBAL PREPARATION PC-SPES; INDIRUBIN; ISATIN; PC SPES; PHYTOSTEROL; PLANT EXTRACT; POLYSACCHARIDE; PROSTATE SPECIFIC ANTIGEN; RUBESCENSINE; RUBESCENSINE B; TRITERPENE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL MODEL; BREAST DISEASE; CANCER CELL CULTURE; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRANTHEMA MORIFOLIUM; DIARRHEA; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GANODERMA LUCIDUM; GLYCYRRHIZA; GYNECODYNIA; GYNECOMASTIA; HERBAL MEDICINE; HUMAN; HUMAN CELL; ISATIS INDIGOTICA; LEG CRAMP; LEG EDEMA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PANAX PSEUDOGINSENG; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE TUMOR; RAT; SABAL; SCUTELLARIA BAICALENSIS; SHORT SURVEY; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING;

EID: 0042911518     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/153473540200100312     Document Type: Short Survey

References (153)

1. 65 Federal Register 1000-1050 (2000) (codified at 21 CFR § 101-93).
2. Israelson LD, Blumenthal M. FDA issues final rules for structure/ function claims for dietary supplements under DSHEA. HerbalGram. 2000;32:32-38.
3. Hartwell JL, Shear MJ. Chemotherapy of cancer: classes of compound under investigation and active components of podophyllin. Cancer Res. 1947;7:716.
4. Hartwell JL. Plants Used Against Cancer. Lawrence, MA: Quarterman; 1972.
5. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR. Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol. 2000;73:347-377.
6. Herfindal ET, Gourley DR, eds. Textbook of Therapeutics. 6th ed. Baltimore, MD: Williams & Wilkins; 1996.
7. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505-2514.
8. Watanabe M, Nakayama T, Shiraishi T, Stemmerman GN, Yatani R. Comparative studies of prostate cancer in Japan and the United States: a review. Urol Oncol. 2000;4:274-283.
9. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin. 1998;48:6-29.
10. Landis SH, Tong T, Bolden S, Wingo PA. Cancer statistics. Cancer J Clin. 1996;46:5-27.
11. Meltzer D, Egleston B, Abdalia I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health. 2001;91:126-128.
12. Waselenko JK, Dawson NA. Management of progressive metastatic prostate cancer. Oncology. 1997;11:1551-1560.
13. Risberg T, Lund E, Wist E, et al. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol. 1998;16:6-12.
14. Moyad MA. Alternative therapies for advanced prostate cancer: what should I tell my patients? Hormone Refractory Prostate Cancer 1999;26:413-417.
15. Fan S, Wang X. Herbal composition for treating prostate cancer: PC-SPES®. US Patent No. 5,665,393 (September 9, 1997).
16. Moyad MA, Hathaway S, Ni HS. Traditional Chinese medicine, acupuncture, and other alternative medicines for prostate cancer: an introduction and the need for more research. Sem Urol Oncol. 1999;17:103-110.
17. Darzynkiewicz Z, Traganos F, Wu JM, Chen S. Chinese herbal mixture in treatment of prostate cancer. Int J Oncol. 2000;17:729-736.
18. PC SPES. Med Lett Drugs Ther. 2001;43:15-16.
19. de la Taille A, Katz A, Vacherot F, et al. Une nouvelle approche nutritionelle. La Presse Méd. 2001;30:561-564.
20. de la Taille A. PC-SPES in prostatic cancer: critical review of the literature. Prog Urol. 2001;11:428-432.
21. DiPaola RS, Kumar P, Hait WN, Weiss RE. State-of-the-art prostate cancer treatment and research: a report from the Cancer Institute of New Jersey. N J Med. 2001;98:23-33.
22. Geliebter J, Mittelman A, Tiwari RK. PC-SPES and prostate cancer. J Nutr. 2001;131:164S-166S.
23. Hawkins EB. From tradition to modernity: Asian therapies for cancer: a first international conference. HerbalGram. 2001;53:64-68.
24. Farnsworth NR, Beecher CWW, Fong HHS. The NAPRALERT database: linking traditional and modern medicine. Essential Drugs Monitor. 1996;20:8-10.
25. Zhang SH, Wan BL. Determination of indigo and indirubin in qingdai (Isatis indigotica) by dual wavelength spectrophotometry. Yao Hsueh Hsueh Pao. 1985;20:301-305.
26. Huang QS, Yoshihira K, Natori N. Isolation of 2-hydroxybutenyl thiocyanate, epigoitrin and adenosine from "banlangen," Isatis indigotica root. Yao Hsueh T'ung Pao. 1981;16:54-55.
27. Zhai SY, Guo JZ. Treatment of 100 cases of acute and chronic dacryocystitis by irrigating the lacrimal passage with banlangen solution. Chung I Tsa Chih. 1987;28:216.
28. Duke JJ, Ayensu ES. Medicinal Plants of China. Algonac, MI: Reference; 1985.
29. Takatsuki S, Narui T, Ekimoto H, Abuki H, Niijima K, Okuyama T. Studies on cytotoxic activity of animal and plant crude drugs. Nat Med. 1996;50:145-157.
30. Fang FD, Wu GW. Review of the anticancer drug indirubin. Chung-Hua Nei K'o Tsa Chih. 1982;7:312-314.
31. Tang W, Eisenbrand G. Chinese Drugs of Plant Origin. Berlin: Springer-Verlag; 1992.
32. Chang XR, Xu QH, Zhu DY, Song GQ, Xu RS. Isolation and structural elucidation of liconeolignan from Glycyrrhiza uralensis. Acta Pharm Sinica. 1983;18:45-50.
33. Canonica L, Russo G, Bombardelli E. Triterpeni della Glycyrrhiza glabra - nota II: acido liquiritico. Gazz Chim Ital. 1966;96:832-842.
34. Liu PY, Hu HF, Yan Z, Lu J, Jiang KK. Colorimetric estimation of glycyrrhizin content in Glycyrrhiza inflata produced in four provinces. Hebei Daxue Xuebao Ziran Kexueban. 1998;18:369-371.
35. Kitagawa I, Chen WZ, Taniyama T, et al. Quantitative determination of constituents in various licorice roots by means of high performance liquid chromatography. Yakugaku Zasshi. 1998;118:519-528.
36. Goryachev VS, Pauzner LE, Muinova SS. Estrogenic activity of Glycyrrhiza glabra and Glycyrrhiza uralensis hay. Materialy po Biologii Vidov Roda Glycyrrhiza. 1970:11-15.
37. Park SY, Kim JW. Screening and isolation of antitumor agents from medicinal plants. Korean J Pharmacog. 1992;23:264-267.
38. Ueki H, Kaibara M, Sakagawa M, Hayashi S. Antitumor activity of plant constituents: I. Yakugakku Zasshi. 1961;81:1641-1644.
39. Woo WS, Lee EB, Han BH. Biological evaluation of Korean medicinal plants: III. Arch Pharmacol Res. 1979;2:127-131.
40. Zhao JF, Kiyohara H, Sun XB, et al. In vitro immunostimulating polysaccharide fractions from roots of Glycyrrhiza uralensis. Phytother Res. 1991;5:206-210.
41. Matsuo R, Ball MA, Kobayashi M, Herndon DN, Pollard RB, Suzuki F. Effects of a traditional Chinese herbal medicine, kanzho-bushi-to, on the resistance of thermally injured mice injected with herpes simplex virus. Int J Immunol. 1994;16:855-863.
42. Jin R, Wan LL, Mitsuishi T, Kodama K, Kurashige S. Immunomodulative effects of Chinese herbs in mice treated with the anti-tumor agent cyclophosphamide. Yakugaku Zasshi. 1994;114:533-538.
43. Matsumoto T, Tanaka M, Yamada H, Cyong JC. Effect of licorice roots on carageenan-induced decrease in immune complexes clearance in mice. J Ethnopharmacol. 1996;53:1-4.
44. Kumagai A. Hormone-like action of licorice and glycyrrhizin. Taisha. 1973;10:632-645.
45. 4-5α- and 5β-reductase in rat liver. Arzneimittelforsch. 1979;29:647-649.
46. Takatsuki S, Narui T, Ekimoto H, Abuki H, Niijima K, Okuyama T. Studies on cytotoxic activity of animal and plant crude drugs. Nat Med. 1996;50:145-157.
47. Sasaki R, Tsunoda S, Matano Y, Saito Y. Antitumor polysaccharides from Panax notoginseng roots. Japanese Patent Kokai Tokkyo Koho No. 02 268,120 (1990).
48. Konoshima T, Takasaki M, Tokuda H. Anti-carcinogenic activity of the roots of Panax notoginseng. Biol Pharm Bull. 1999;22:1150-1152.
49. Takao K. Cancer chemopreventive activities of Panax notoginseng and ginsenoside RG1. Stud Plant Sci. 1999;6:36-42.
50. Lin WS, Cahn WCL, Hew CS. Superoxide and traditional Chinese medicines. J Ethnopharmacol. 1995;48:165-171.
51. Li XJ, Shen JJ, Xin HB, Zhang BH. Protective effects of panaxatriol saponins isolated from Panax notoginseng on ischemic-reperfused injury and arrythmia in isolated rat hearts. Zhongguo Yaolixue Yu Dulixue Zazhi. 1992;6:272-274.
52. Zhou J, Wu MZ, Taniyama S, et al. Bioactive saponins and glycosides: VIII: notoginseng: new dammarane-type triterpene oligoglycosides, notoginsenosides-A, -B, -C, and -D, from the dried root of Panax notoginseng. Chem Pharm Bull (Tokyo). 1981;29:2844-2850.
53. Van Breemen RB, Huang CR, Lu ZZ, Rimando A, Fong HHS, Fitzloff JF. Electrospray liquid chromatography/mass spectrometry of ginsenosides. Analytical Chemistry. 1995;67:3985-3989.
54. Fitzloff JF, Yat P, Lu ZZ, et al. Perspectives on the quality assurance of ginseng products in North America. Paper presented at: 7th International Symposium on Ginseng; September 22-25, 1998; Seoul, South Korea.
55. Sone Y, Okuda R, Wada N, Kishida E, Misaki A. Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agricultural and Biological Chemistry. 1985;49:2641-2653.
56. Maruyama H, Yamazaki K, Murofushi S, Konda C, Ikekawa T. Antitumor activity of Sarcodon aspratus and Ganoderma lucidum. J Pharmacobiodyn. 1989;12:118-123.
57. Furusawa E, Chou SC, Furusawa S, Hirazumi A, Dang Y. Antitumor activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in synergenic mice. Phytother Res. 1992;6:300-304.
58. Dornberger K, Gutsche W, Horschak R, Zureck A. Microbiological and cytological screening of potentially carsinostatic, membrane active mushroom extracts that interfere with nucleic acid metabolism. Z Allg Mikrobiol. 1978;18:647-664.
59. Lovy A, Knowles B, Labbe R, Nolan L. Activity of edible mushrooms against the growth of human T4 leukemic cancer cells, HeLa cervical cancer cells, and Plasmodium falciparum. J Herbs Spices Med Plants. 1999;6:49-57.
60. Shin HW, Kim HW, Choi EC, Toh SH, Kim KB. Studies on inorganic composition and immunopotentiating activity of Ganoderma lucidum in Korea. Korean J Pharmacog. 1985;16:181-190.
61. Chen WC, Hau DM, Lee SS. Effects of Ganoderma lucidum and krestin on cellular incompetence in gamma-ray-irradiated mice. Am J Chin Med. 1995;23:71-80.
62. Xu WD, Hu TX, Yang QY. Study of the immunoregulation effect of Ganoderma lucidum extracts on human peripheral blood cells. Zhonghua Yaoxue Zazhi. 2000;35:559-561.
63. Guan HC, Cong Z. Effects of ling zhi polysaccharide D6 on the biosynthesis of nucleic acid and protein and its preliminary analysis. Yao Hsueh T-ung Pao. 1982;17:177-178.
64. Mizushina YK, Watanabe I, Togashi H, et al. An ergosterol peroxide, a natural product that selectively enhances the inhibitory effect on linolenic acid on DNA polymerase beta. Biol Pharm Bull. 1998;21:444-448.
65. Lei LS, Lin ZB. Effects of Ganoderma polysaccharides on the activity of DNA polymerase alpha of splenocytes and immune function in aged mice. Yao Hsueh Hsueh Pao. 1993;28:577-582.
66. Cao CF, Hou GH, Jiang QH, Zhou YB, Xie W, Xu X. Mechanism of action of Ganoderma lucidum polysaccharides. Shandong Yike Daxue Xuebao. 1992;30:203-206.
67. Lee SS, Wei YH, Chen CF, Wang SY, Chen KY. Antitumor effects of Ganoderma lucidum. J Chin Med. 1994;5:152-153.
68. Lieu CW, Lee SS, Wang SY. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res. 1992;12:1211-1215.
69. Wang SY, Hsu ML, Hsu HC, et al. The antitumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997;70:699-705.
70. Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against Meth-A and LLC tumor cells. Chem Pharm Bull. 2000;48:1026-1033.
71. Wu TS, Shi LS, Kuo SC. Cytotoxicity of Ganoderma lucidum triterpenes. J Nat Prod. 2001;64:1121-1122.
72. Sharma SC, Tanwar RC, Kaur S. Contact dermatitis from chrysanthemums in India. Contact Dermatitis. 1989;21:69-71.
73. Kim JS, Kim GH, Kim IH. Anti-steroidogenic properties of Scutellaria and Pueraria plant extracts. Korean J Pharmacog. 1986;17:148-152.
74. Pan PC. The application of Chinese traditional medicine in the treatment of vaginal cancer. Chin J Obstet Gynecol. 1960;8:156-162.
75. Ryu SH, Ahn BZ, Pack MY. The cytotoxic principle of Scutellariae radix against L1210 cell. Planta Med. 1985;51:355-356.
76. Watanabe K, Inada Y, Ikegami H, et al. In vitro immunomodulatory effects of traditional Kampo medicine on peripheral mononuclear cells from patients with HIV infection. Int J Orient Med. 1990;15:1-9.
77. Schroeder E. Preliminary study of Chinese anticancer drugs. Anais Paulistas de Medicina e Cirugia. 1978;105:67-94.
78. Wong BY, Lau BHS, Teel RW. Chinese medicinal herbs modulate mutagenesis, DNA binding and metabolism of benzo[a]pyrene 7,8-dihydrodiol and benzo[a]pyrene 7,8-dihydrodiol-9,10-epoxide. Cancer Lett. 1992;62:123-131.
79. Inada Y, Watanabe K, Kamiyama M, Kanemitsu T, Clark WS, Lange M. In vitro immunomodulatory effects of traditional Kampo medicine (Sho-Saiko-to) on peripheral mononuclear cells in patients with AIDS. Biomed Pharmacother. 1990;44:17-19.
80. Yu LR, Liu ML, Zhang YH. TLC densitometry of baicalin and wogonoside in Scutellaria. Yaowu Fenxi Zazhi. 1983;3:18-21.
81. Zhang YY, Guo YZ, Onda M, et al. Four flavonoids from Scutellaria baicalensis. Phytochemistry 1994;35:511-514.
82. Kubo M, Matsuda H, Tani T, Arichi S, Kimura Y, Okuda H. Studies on Scutellariae radix: XII: anti-thrombic actions of various flavonoids from Scutellariae radix. Chem Pharm Bull (Tokyo). 1985;33:2411-2415.
83. Huang HC, Hsieh LM, Chen HW, Lin YS, Chen JS. Effects of baicalein and esculetin on transduction signals and growth factor expression in T-lymphoid leukemia cells. Eur J Pharmacol. 1994;268:73-78.
84. Motoo Y, Sawabu N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett. 1994;86:91-95.
85. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specifc DNA cleavage by mammalian topoisomerase II induced by novel flavone and catechin derivatives. Biochem J. 1992;282:885-889.
86. Matsuzaki Y, Kurokawa N, Terai S, Matsumura Y, Kobayashi N, Okita K. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res. 1996;87:170-177.
87. Nikaido T, Ohmoto T, Kinoshita T, et al. Inhibition of adenosine 3′,5′-cyclic monophosphate phosphodiesterase by flavonoids III. Chem Pharm Bull. 1989;37:1392-1396.
88. Hamada H, Hiramatsu M, Edamatsu R, Mori A. Free radical scavenging action of baicalein. Arch Biochem Biophys. 1993;306:261-266.
89. Hara H, Sukamoto T, Ohtaka H, et al. Effects of baicalein and alpha-tocopherol on lipid peroxidation, free-radical scavenging activity and 12-O-tetradecanoylphorbol acetate-induced ear edema. Eur J Pharmacol 1992;221:193-198.
90. Konoshima T, Kokumai M, Kozuka M, et al. Studies on inhibitors of skin tunor promotion: XI: inhibitory effects of flavonoids from Scutellaria baicalensis on Epstein-Barr virus activation and their anti-tumor promoting activities. Chem Pharm Bull. 1992;40:531-533.
91. Kato R, Nakadate A, Yamamoto S. Looxygenase inhibition and tumor promoter inhibition by medicinal plant compounds. Wakan Iyaku Gakkaishi. 1985;2:162-163.
92. Chen S, Ruan Q, Bedner E, et al. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Proliferation. 2001;34:293-304.
93. Chan FL, Choi HL, Chen ZY, Chan PSF, Huang Y. Induction of apoptosis in prostate cancer cell lines by a flavonoid, baicalin. Cancer Lett. 2000;160:219-228.
94. Coffey RNT, Watson RWG, Fitzpatrick JM. Signalling for the capsases: their role in prostate cell apoptosis. J Urol. 2001;165:5-14.
95. Li JC, Sun HD, Lin ZW. The structure of lushanrubescensin E. Yunnan Zhiwu Yanjiu. 1988;9:485-488.
96. Yu JJ, Reed E. Preliminary study of the effect of selected Chinese natural drugs on human ovarian cancer cells. Oncol Rep. 1995;2:571-575.
97. Sun HD, Lin CW, Chin CJ, Tao JH, Chao CC. Chemical ingredients of Rabdosia rubescens, an antitumor plant. Yunnan Zhiwu Yanjiu. 1981;3:95-100.
98. A new antitumor sustance-rubescensine. K'o Hsueh T'ung Pao. 1978;23:53.
99. Chang TL, Chen CY, Miau CH, Chao CT, Sun HT, Liu CW. Rubesensine B-another effective antitumor agent in Rabdosia rubescens. K'o Hsueh T'ung Pao. 1980;25:1051-1053.
100. Schöpflin G, Rimpler H, Hänsel R. Beta-sitosterol as a possible hormone of sabal fruits. Planta Med. 1966;14:402-407.
101. Hatinguias P, Belle R, Basso Y, Ribet JP, Bauer M, Pousset JL. Composition of the hexane extract from Serenoa repens fruits. Trav Soc Pharm (Montpellier). 1981;41:253-262.
102. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48:12-20.
103. Elghamry MI, Hansel R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens), a small estrogenic plant. Experientia. 1969;25:828.
104. 2 extracts of Serenoa repens fruits. Fitoterapia. 1997;68:355-358.
105. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5α-reductase types I and II inhibitor-new evidence in a co-culture model of BPH. Prostate. 1999;40:232-241.
106. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990;37:375-378.
107. Niederprüm HJ, Schweikert HU, Zänker KS. Testosterone 5α-reductase inhibition by free fatty acids from Sabal serrulata fruits. Phytomedicine. 1994;1:127-133.
108. El-Shiekh MM, Dakkak MR, Saddique A. The effect of Permixon on androgen receptors. Acta Obstet Gynecol Scand. 1988;67:397-399.
109. Ravenna L, Di Silverio F, Russo MA, et al. Effects of lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate. 1996;29:219-230.
110. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride, a 5α-reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α-reductase inhibition. The Prostate. 1993;22:43-51.
111. Wang XH. A report on 60 cases of functional uterine hemorrhage treated with "Xian He Gu Gong Tang." Zhejiang-Zhongyi Zazhi. 1982;17:272-276.
112. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996;88:908-917.
113. Citrin DL, Kies MS, Wallemark C, et al. A phase II study of high dose estrogen (diethylstilbestrol diphosphate) in prostate cancer. Cancer. 1985;56:456-460.
114. Ferro MA, Gilliat D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma: use of serum prostate antigen to monitor response. Urology. 1989;34:134-138.
115. Fan S, Wang X. Composition of herbal extracts: SPES®. US Patent No. 5,417,979 (May 1995).
116. Hsieh T, Chen SS, Wang X, Wu JM. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int. 1997;42:535-544.
117. Hsieh TC, Ng CY, Chang CC, Chen SS, Mittelman A, Wu JM. Induction of apoptosis and down-regulation of bcl-6 in mutu 1 cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol. 1998;13:1199-1202.
118. Chang CC, Ye BH, Chaganati RSK, Dalla-Favera R. bcl-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A. 1996;93:6947-6952.
119. Liang R, Chan WP, Kwong YL, et al. bcl-6 gene hypermutations in diffuse large B-cell lymphoma of primary gastric origin. Br J Hematol. 1997;99:668-670.
120. Halicka HD, Ardelt B, Juan G, et al. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. Int J Oncol. 1997;11:437-448.
121. Adam L, Crepin M, Israel L. Tumor growth inhibition, apoptosis, and bcl-2 down regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res. 1997;57:1023-1029.
122. Kubota T, Hisatake J, Hisatake Y, et al. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. The Prostate. 2000;42:163-171.
123. de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. British Journal of Urology International. 1999;84:845-850.
124. de la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol. 2000;164:1229-1234.
125. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785-791.
126. Tiwari RK, Geliebter J, Garikapaty VP, Yedavelli SP, Chen S, Mittelman A. Antitumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol. 1999;14:713-719.
127. Rafi MM, Rosen RT, Vassil A, et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000;20:2653-2658.
128. Shibata S, Inoue H, Iwata S, et al. Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflata root on inflammatory ear edema and tumor promotion in mice. Planta Med. 1991;57:221-224.
129. Zhai L, Blom J, Chen M, Christensen SB, Kharazmi A. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother. 1995;39:2742-2748.
130. Sadava D, Ahn J, Zhan M, Pang ML, Ding J, Kane SE. Effects of four Chinese herbal extracts on drug-sensitive and multi-drug resistant small-cell lung carcinoma cells. Cancer Chemother Pharmcol. 2002;49:261-266.
131. Hsieh TZ, Wu JM. Mechanism of action of herbal supplement PC-SPES: elucidation of effects on individual herbs of PC-SPES on proliferation and prostate specific antigen gene expression in androgen-dependent LNCaP cells. Int J Oncol. 2002;20:583-588.
132. Bonkoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999;155:641-647.
133. Bonkoff H, Fixemer T, Hunsicker I, Remberger K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. The Prostate. 2001;48:285-291.
134. Moyad MA, Pienta KJ, Montie JE. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology. 1999;54:319-324.
135. Porterfield H. Survey of UsToo members and other prostate cancer patients to evaluate the efficacy and safety of PC-SPES. Mol Urol. 1999;3:333-335.
136. Porterfield H. UsToo PC-SPES surveys: review of studies and update of previous survey results. Mol Urol. 2000;4:289-293.
137. de la Taille A, Hayek OR, Burchardt M, Burchardt T, Katz AE. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Alternative Complementary Med. 2000;6:449-451.
138. Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol. 2001;8:1326-1329.
139. Kameda H, Small EJ, Reese DM, et al. A phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer (PCa) [Abstract No. 1230]. Proc ASCO. 1999;18.
140. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. British Journal of Urology International. 2000;85:481-485.
141. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595-3603.
142. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52:257-260.
143. Oh WK, George DJ, Hackman K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology. 2001;57:122-126.
144. Aprikian AG, Fair WR, Reuter VE, et al. Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with advanced prostate cancer. Br J Urol. 1994;74:630-636.
145. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPES interact with warfarin? J Urol. 2002;167:1793.
146. Oh WK, George DJ, Kantoff PW. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate cancer: report of four cases. Cancer. 2002;94:686-689.
147. Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med. 2001;345:1213-1214.
148. World Health Organization. Quality Control Methods for Medicinal Plant Materials. Geneva: World Health Organization; 1998.
149. Cordell GA. What's in a name? Evaluating the safety and potency of commercial phytotherapeutical products. Paper presented at: International Forum on Traditional Medicine; 1999; Toyama, Japan.
150. Cordell GA. Recent developments in the study of biologically active natural products. ACGC Chem Res Commun. 2002;14:31-62.
151. Cordell GA. Perspectives on the future role of plants in drug discovery. Paper presented at: Fourth International Symposium on Plants as Medicines; 2001; Jardín Botánico Nacional, Santo Domingo, Dominican Republic.
152. Soller RW. Will FDA get the funds to effectively regulate dietary supplements? Journal of the American Nutrition Association. 2001;3:3-5.
153. Bayne HM. FDA publishes new draft guidance for botanical drug products. HerbalGram. 2000;50:68-69.